What to expect when you take Navelbine and have Bone loss?

Do you take Navelbine and have Bone loss? Find out below what new side effects and undetected conditions people who are 50-59 years old may have. This prediction is created after we perform predictive analysis on health care big data. It will be updated regularly.

How to use this study: bring a copy to your health teams to ensure drug risks and benefits are fully discussed and understood.

Who is eHealthMe: we are a data analysis company who specializes in health care industry. Our original studies have been referenced on 500+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and EANO. On eHealthMe, you can research drugs and monitor them (see testimonials).



On Sep, 21, 2018

1,671 reports have been studied.


Females aged 50 to 59 :

1,160 related reports were analyzed:

Most common symptoms:

Abdominal pain
  • 6.29% for females aged 50 (±5) who take Navelbine
Agranulocytosis
  • 9.48% for females aged 50 (±5) who take Navelbine
Anaemia
  • 12.16% for females aged 50 (±5) who take Navelbine
Appetite - decreased
  • 5.26% for females aged 50 (±5) who take Navelbine
Aseptic necrosis
  • 9.4% for females aged 50 (±5) who take Navelbine
Atelectasis
  • 6.55% for females aged 50 (±5) who take Navelbine
Back pain
  • 10.34% for females aged 50 (±5) who take Navelbine
Bone disorder
  • 13.02% for females aged 50 (±5) who take Navelbine
Bone pain
  • 6.64% for females aged 50 (±5) who take Navelbine
Chest pain
  • 6.98% for females aged 50 (±5) who take Navelbine
Constipation
  • 8.79% for females aged 50 (±5) who take Navelbine
Cough
  • 5.09% for females aged 50 (±5) who take Navelbine
Death
  • 6.03% for females aged 50 (±5) who take Navelbine
Decreased interest
  • 5.17% for females aged 50 (±5) who take Navelbine
Depression
  • 5.0% for females aged 50 (±5) who take Navelbine
Diarrhea
  • 8.1% for females aged 50 (±5) who take Navelbine
Dizziness
  • 8.53% for females aged 50 (±5) who take Navelbine
Dyspnea
  • 16.47% for females aged 50 (±5) who take Navelbine
Fall
  • 5.95% for females aged 50 (±5) who take Navelbine
Fatigue
  • 12.07% for females aged 50 (±5) who take Navelbine
Fever
  • 16.21% for females aged 50 (±5) who take Navelbine
Gastroesophageal reflux disease
  • 5.43% for females aged 50 (±5) who take Navelbine
General physical health deterioration
  • 6.12% for females aged 50 (±5) who take Navelbine
Headache
  • 6.47% for females aged 50 (±5) who take Navelbine
High blood pressure
  • 6.98% for females aged 50 (±5) who take Navelbine
Hypoaesthesia
  • 8.71% for females aged 50 (±5) who take Navelbine
Impaired healing
  • 8.45% for females aged 50 (±5) who take Navelbine
Infection
  • 5.17% for females aged 50 (±5) who take Navelbine
Injury
  • 7.59% for females aged 50 (±5) who take Navelbine
Joint pain
  • 9.14% for females aged 50 (±5) who take Navelbine
Malignant neoplasm progression
  • 6.64% for females aged 50 (±5) who take Navelbine
Metastases to bone
  • 11.12% for females aged 50 (±5) who take Navelbine
Metastases to central nervous system
  • 6.55% for females aged 50 (±5) who take Navelbine
Metastases to liver
  • 7.76% for females aged 50 (±5) who take Navelbine
Metastases to lung
  • 8.1% for females aged 50 (±5) who take Navelbine
Nausea
  • 12.16% for females aged 50 (±5) who take Navelbine
Nausea and vomiting
  • 8.02% for females aged 50 (±5) who take Navelbine
Neoplasm malignant
  • 5.95% for females aged 50 (±5) who take Navelbine
Oedema peripheral
  • 6.72% for females aged 50 (±5) who take Navelbine
Oral disorder
  • 6.29% for females aged 50 (±5) who take Navelbine
Osteoarthritis
  • 6.12% for females aged 50 (±5) who take Navelbine
Osteomyelitis
  • 8.71% for females aged 50 (±5) who take Navelbine
Osteonecrosis of jaw
  • 15.34% for females aged 50 (±5) who take Navelbine
Pain
  • 17.59% for females aged 50 (±5) who take Navelbine
Pain in jaw
  • 6.9% for females aged 50 (±5) who take Navelbine
Paraesthesia
  • 6.81% for females aged 50 (±5) who take Navelbine
Pleural effusion
  • 10.43% for females aged 50 (±5) who take Navelbine
Pneumonia
  • 5.86% for females aged 50 (±5) who take Navelbine
Rashes
  • 7.33% for females aged 50 (±5) who take Navelbine
Spinal osteoarthritis
  • 6.55% for females aged 50 (±5) who take Navelbine
Stomatitis
  • 5.69% for females aged 50 (±5) who take Navelbine
Stress and anxiety
  • 14.48% for females aged 50 (±5) who take Navelbine
Swelling
  • 6.81% for females aged 50 (±5) who take Navelbine
Thrombocytopenia
  • 6.29% for females aged 50 (±5) who take Navelbine
Tooth extraction
  • 9.66% for females aged 50 (±5) who take Navelbine
Toothaches
  • 6.98% for females aged 50 (±5) who take Navelbine
Urinary tract infection
  • 5.09% for females aged 50 (±5) who take Navelbine
Weakness
  • 10.69% for females aged 50 (±5) who take Navelbine
Weight decreased
  • 6.64% for females aged 50 (±5) who take Navelbine

Most common co-existing conditions:

Breast cancer metastatic
  • 16.64% for females aged 50 (±5) who take Navelbine
Metastases to bone
  • 13.62% for females aged 50 (±5) who take Navelbine
back to top

Males aged 50 to 59 :

511 related reports were analyzed:

Most common symptoms:

Agranulocytosis
  • 16.44% for males aged 50 (±5) who take Navelbine
Anorexia
  • 5.09% for males aged 50 (±5) who take Navelbine
Back pain
  • 5.68% for males aged 50 (±5) who take Navelbine
Chest pain
  • 6.65% for males aged 50 (±5) who take Navelbine
Cough
  • 6.26% for males aged 50 (±5) who take Navelbine
Dehydration
  • 5.87% for males aged 50 (±5) who take Navelbine
Diarrhea
  • 5.09% for males aged 50 (±5) who take Navelbine
Dyspnea
  • 6.46% for males aged 50 (±5) who take Navelbine
Fever
  • 19.18% for males aged 50 (±5) who take Navelbine
Haemoglobin decreased
  • 5.87% for males aged 50 (±5) who take Navelbine
Nausea
  • 6.85% for males aged 50 (±5) who take Navelbine
Pneumonia
  • 5.09% for males aged 50 (±5) who take Navelbine
Thrombocytopenia
  • 8.81% for males aged 50 (±5) who take Navelbine
Weakness
  • 6.65% for males aged 50 (±5) who take Navelbine

Most common co-existing conditions:

Lung cancer - non-small cell
  • 12.52% for males aged 50 (±5) who take Navelbine
back to top

Do you take Navelbine and have Bone loss:

  • To personalize this prediction to you, including to your gender, age, personal and family history, and more: Click here

Related studies

navelbine

Navelbine has active ingredients of vinorelbine tartrate. It is often used in breast cancer. (latest outcomes from Navelbine 7,479 users)

bone loss

Bone loss has been reported by people with osteoporosis, osteopenia, rheumatoid arthritis, high blood pressure, gastroesophageal reflux disease (latest reports from 4,161 Bone loss patients).

General study

Recent updates

Recent general studies
Recent personal studies

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on ePatient.care is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the ePatient.care site and its content is at your own risk.